Processa Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing a pipeline of Next Generation Cancer therapy (NGC) small molecules. Its oncology pipeline consists of NGC-Cap and NGC-Iri (also identified as PCS6422 and PCS11T, respectively) and two non-oncology drugs (PCS12852 and PCS499). NGC-Cap is a combination of PCS6422 and capecitabine, capecitabine being the oral prodrug of the cancer drug 5-fluorouracil. PCS3117 is an oral analog of gemcitabine that is converted to its active metabolite by a different enzyme system than gemcitabine. PCS11T is a prodrug of the active metabolite of irinotecan. PCS12852 is a specific and potent 5HT4 agonist that is in Phase IIB and is a potential treatment for diabetic gastroparesis patients. PCS499 is a drug that can be used to treat unmet medical needs and conditions caused by multiple pathophysiological changes. Its pipelines also include VT-7208, a Bruton's tyrosine kinase inhibitor therapy for immune-mediated diseases.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
17/08/26	US$2.220	-8.64%	41,979
14/08/26	US$2.430	-2.80%	50,194
13/08/26	US$2.500	-2.34%	38,451
12/08/26	US$2.560	-2.66%	82,681
11/08/26	US$2.630	+0.77%	45,618

Delayed Quote Nasdaq

More quotes

Income Statement and Estimates

More financial data

Quarterly revenue - Rate of surprise

Company calendar

Delayed Nasdaq 17:24:09 17/08/2026 BST			5-day change	1st Jan Change
2.220 ^USD	-8.64%		-14.94%	-22.92%

08-14	Processa Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
07-29	Processa Pharmaceuticals, Inc. acquired Vidya Therapeutics, Inc. for approximately $320 million.	CI

Market Cap	6.68M 5.77M 5.41M 4.93M 9.27M 639M 9.4M 63.45M 24.86M 320M 25.09M 24.55M 1.06B	P/E 2024	-0.23x	P/E 2025	-0.28x
Enterprise Value	1.15M 989K 928K 845K 1.59M 110M 1.61M 10.88M 4.26M 54.89M 4.3M 4.21M 183M	EV / Sales 2024	-	EV / Sales 2025	-
Free-Float	87.65%	Yield 2024 *	-	Yield 2025	-

08-14	Processa Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
07-29	Processa Pharmaceuticals, Inc. acquired Vidya Therapeutics, Inc. for approximately $320 million.	CI
07-29	Processa Pharmaceuticals, Inc. - M&A Call
07-29	Processa Pharmaceuticals, Inc. announced that it expects to receive $200 million in funding from a group of investors	CI
07-29	Processa buys Vidya Therapeutics, raises $200 million for drug trials	RE
07-29	Processa Pharmaceuticals, Inc. Announces Appointment of Sheila Gujrathi as Director	CI
07-27	Processa Pharmaceuticals, Inc. announced that it expects to receive $200 million in funding	CI
07-27	Deals of the day-Mergers and acquisitions	RE
05-07	Processa Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
04-30	Processa Pharmaceuticals, Inc. Announces Transition of Employment Status of Sian Bigora, Chief Development and Regulatory Officer, Effective May 1, 2026	CI
03-20	Bio-Path Holdings, Inc. Announces Scientific Advisory Board Appointments, Effective February 10, 2026	CI
03-18	Processa Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
03-17	Processa Pharmaceuticals, Inc. Auditor Raises 'Going Concern' Doubt	CI

11-05	Processa Pharmaceuticals Announces Poster Presentation of Adaptive Phase 2/3 Pcs499 Study in Fsgs At Asn Kidney Week 2025	CI
25/04/24	Top Midday Gainers	MT
25/04/24	HC Wainwright Starts Processa Pharmaceuticals With Buy Rating, $8 Price Target	MT
04/04/23	Benchmark Adjusts Price Target on Processa Pharmaceuticals to $4 From $9, Keeps Speculative Buy Rating	MT
03/04/23	Oppenheimer Adjusts Processa Pharmaceuticals Price Target to $3 From $5, Maintains Outperform Rating	MT

Processa Pharmaceuticals, Inc. Share Price

Stocks

PCSA

US74275C4033

Biotechnology & Medical Research

Valuation: Processa Pharmaceuticals, Inc.

Chart: Processa Pharmaceuticals, Inc.

Latest news : Processa Pharmaceuticals, Inc.

Last Transcript: Processa Pharmaceuticals, Inc.

Analysts' recommendations: Processa Pharmaceuticals, Inc.

Press Releases: Processa Pharmaceuticals, Inc.

News in other languages: Processa Pharmaceuticals, Inc.

Quotes and Performance

Course Extremes

Managers and Directors: Processa Pharmaceuticals, Inc.

Latest insider transactions

Bio Therapeutic Drugs

Financials

Company Profile

Quotes

Income Statement and Estimates

Quarterly revenue - Rate of surprise

07-31	Processa Pharmaceuticals : Initial Statement of Beneficial Ownership (Form 3)	PU
07-29	PROCESSA PHARMACEUTICALS, INC. ANNOUNCES ACQUISITION OF VIDYA THERAPEUTICS, INC. AND APPROXIMATELY $200 MILLION CONCURRENT PRIVATE PLACEMENT TO ADVANCE BTK INHIBITOR, VT-7208, IN MULTIPLE DISEASE AREAS	AQ
05-08	Processa Pharmaceuticals : Quarterly Report for Quarter Ending March 31, 2026 (Form 10-Q)	PU
01-12	Processa Pharmaceuticals to Attend 44th Annual J.P. Morgan Healthcare Conference	AQ
01-05	Processa Pharmaceuticals Completes Enrollment of 20th Patient for Formal Interim Analysis in Phase 2 NGC-Cap Breast Cancer Study	AQ

24/08/23	Graco: un compounder di qualità sotto gli occhi di tutti
22/08/23	Graco Inc.: Un compounder de calidad bajo el radar
22/08/23	Graco : un compounder de qualité sous les radars

1 day	-9.05%
1 week	-14.94%
Current month	+3.26%
1 month	-3.90%
3 months	-19.27%
6 months	+1.83%
Current year	-22.92%

1 week	2.17	2.68
1 month	1.8	3.11
Current year	1.67	3.8
1 year	1.67	14.24
3 years	1.67	450
5 years	1.67	4,495.35
10 years	1.67	125,195.11

Manager	Title	Age	Since
George Ng CEO	Chief Executive Officer	52	07/08/2023
Patrick Lin IRC	Investor Relations Contact	60	28/03/2011
Wendy Guy ADM	Chief Administrative Officer	61	03/10/2017

Director	Title	Age	Since
David Young CHM	Chairman	73	28/03/2011
Justin Yorke CHM	Chairman	60	15/08/2022
Geraldine Pannu BRD	Director/Board Member	56	12/02/2020

Date	Insider	Type	Main position	Quantity	% Market Cap.
08/08/26	George Ng	Fiscal year	Chief Executive Officer	3,200	0.1156%
26/07/26	Russell Skibsted	Other	Chief Financial Officer	11,883	0.4293%
26/07/26	George Ng	Other	Chief Executive Officer	9,384	0.3390%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
PROCESSA PHARMACEUTICALS, INC.	-8.64%	-14.94%	-59.10%	-98.86%	6.68M
WUXI APPTEC CO., LTD.	+4.80%	+7.80%	+70.64%	+114.21%	70.07B
ARGENX SE	+17.12%	+11.50%	+49.15%	+87.30%	52.87B
INSMED INCORPORATED	+2.32%	-5.75%	-0.21%	+478.08%	27.02B
WUXI BIOLOGICS (CAYMAN) INC.	+2.26%	+0.65%	+49.19%	+10.30%	23.61B
BIONTECH SE	-1.50%	-1.11%	-18.46%	-18.95%	23.38B
PHARMAESSENTIA CORPORATION	-6.00%	+13.71%	+244.39%	+443.26%	19.43B
GENMAB A/S	+3.80%	+5.62%	+39.57%	-15.26%	18.75B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	+0.38%	-3.15%	+20.39%	+589.77%	15.85B
EXELIXIS, INC.	+2.20%	-1.19%	+38.59%	+149.19%	12.7B
Average	+1.68%	-2.42%	+43.41%	+173.90%	26.37B
Weighted average by Cap.	+5.01%	-1.14%	+55.27%	+170.30%

	2024	2025
Net sales	-	-
Net income	-11.85M -10.23M -9.6M -8.74M -16.44M -1.13B -16.66M -113M -44.09M -568M -44.49M -43.53M -1.89B	-13.56M -11.71M -10.99M -10.01M -18.81M -1.3B -19.07M -129M -50.46M -650M -50.92M -49.82M -2.16B
Net Debt	-1.12M -965K -905K -825K -1.55M -107M -1.57M -10.61M -4.16M -53.55M -4.2M -4.11M -178M	-5.54M -4.78M -4.48M -4.08M -7.68M -529M -7.79M -52.57M -20.6M -265M -20.79M -20.34M -882M